Our Story

Enabling Immunity

Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is to leverage multinational pharmaceutical companies to facilitate and maximize worldwide patient accessibility.

The AbelZeta Difference

Our goal is to rapidly advance innovative T cell immunotherapies by leveraging proof-of-concept data from early-stage clinical trials. This approach enables informed decision-making promptly, enhancing the overall success of drug development. Clinical data is essential for understanding performance for this new class of cell-based immunotherapies.

AbelZeta has endeavored to test drug candidates as fast as possible in investigator-initiated trials in order to de-risk and improve the efficiency of the drug candidate selection process.

Core Strengths

Our numerous therapeutic development pursuits, including best-in-class and best-in-disease potential candidates are built on our core strengths that we have been optimizing for more than 14 years.

Proven Target & Optimal Design

Pipeline assets optimized internally by maximizing specificity while minimizing toxicity.

Exceptional Early Clinical Results

Early clinical data showed best-in-class and best-in-disease potential for multiple assets.

Partnered Lead Program

Partnerships with global pharma for hematological cancer & solid tumors to leverage their strong expertise in clinical development and global commercialization.

Platform Potential

In-house platform established to facilitate the development of multiple cell therapies to target both cancer and I&I diseases.